World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 2
Page: 720-735

INTRACOCHLEAR DRUG DELIVERY SYSTEM: CURRENT STATUS AND FUTURE PROSPECTS

Manisha Lavate*, Sujit Karpe, Ritesh Shinde, Pranavraj Bhosale and Akshay Shrimal

Sojar College of Pharmacy, Khandvi Tal. Barshi, Dist. Solapur.

Article Received: 04 March 2025 | | ***Article Revised: 27 March 2025*** | | ***Article Accepted: 16 April 2025***

***Corresponding Author: Manisha Lavate**
Sojar College of Pharmacy, Khandvi Tal. Barshi, Dist. Solapur.
DOI: https://doi.org/10.5281/zenodo.15273901

How to cite this Article: Manisha Lavate, Sujit Karpe, Ritesh Shinde, Pranavraj Bhosale and Akshay Shrimal (2025). INTRACOCHLEAR DRUG DELIVERY SYSTEM: CURRENT STATUS AND FUTURE PROSPECTS. World Journal of Pharmaceutical Science and Research, 4(2), 720-735. https://doi.org/10.5281/zenodo.15273901

ABSTRACT

Novel treatment methods for millions of patients are being made possible by developments in molecular biology and the fundamental knowledge of the mechanisms behind sensorineural hearing loss and other inner ear disorders. New technologies will be needed to deliver these molecules safely and effectively, though, as the cochlea is a particularly difficult target for pharmacological therapy. New delivery methods based on microfluidic technology are demonstrating potential as a direct intracochlear delivery method. In the end, these devices could be used to distribute regenerative chemicals over a prolonged period of time to help patients with a variety of auditory illnesses regain their hearing. This article's goal is to give a succinct overview of intracochlear medication delivery methods that are presently being developed and may eventually be used in conjunction with newly discovered therapeutic chemicals to treat inner ear disorders. This study focuses on the latest improvements in intratympanic drug delivery; methods that use new biomaterials and other recent advancements are also included.There is a new chance to treat inner ear illnesses better thanks to these inner ear medicine delivery devices.

KEYWORDS: Intracochlear; Drug Delivery Microfluidic Technology; Inner Ear Medicine Delivery Devices; Sensorineural Hearing Loss; Intratympanic Drug Delivery.

INTRODUCTION

Background Noise exposure, ototoxic drugs, mutations in genes associated with hearing loss, and age-related degeneration severely impacts the quality of life because it leads to hearing loss. The cochlea, this snug and coiled little snail shell located away in the inner ear plays an important part in audiation, where vibrations from sound are converted into electrochemical signals in the neurons. Delivering drugs at the granular level needed with a systemic approach proves difficult because of the delicate nature of the cochlea structure, and so therapies are still out of reach.

Significance Intracochlear drug delivery (ICDD) have emerged as a theoretical therapeutic paradigm that seeks to deliver therapeutic molecules directly to the cochlea while minimizing exposure to systemic circulation, and potentially minimizing side effects.

Driven by the increasing incidence of inner ear disorders, scientists have made significant advances in recognizing the basic mechanisms and molecular biology of inner ear disorders. They have also discovered promising avenues for inner ear hair cell and neural cell regeneration and function restoration. These strategies include the application of neurotrophin-based systems, RNA interference, gene therapy, and stem cells. Even though there are still many obstacles to overcome before these medications may be used in clinical settings, they have the potential to help patients who are now without therapy for these severe illnesses regain their hearing and other inner ear functions.

Micropumps with active or passive control systems are commonly used in intracochlear delivery systems, which can be used alone or in conjunction with a cochlear implant. The use of passive osmotic pumps, which are tiny enough to allow for implantation but have a short lifespan and no control over delivery parameters, has been the focus of early research. Microfluidic devices have surfaced in recent years, offering reciprocating delivery via a micropump or continuous drug infusion.

Disease of the Inner Ear and Their Treatment Approaches

a. Considerations for Drug Delivery Systems Based on Cochlear Physiology and Function

The cochlea, an organ of hearing located in the inner ear together with the vestibular organ, is responsible for converting mechanical impulses from the middle ear into electrical signals that proceed to the brainstem through the auditory nerve. The cochlea's small size and remote location make direct medication administration difficult. The human cochlea is around 32 mm long and is made up of three coiled tubes filled with fluid: the scala tympani (ST), scala vestibuli, and scala media.[22] One structure that may be used for direct intracochlear delivery is the round window membrane (RWM), where the ST stops, as will be covered later. The oval window, which contains the stapes or footplate that relays mechanical impulses from the middle ear, is where the scala vestibuli ends. The helicotrema connects the tympani and scala vestibule at the cochlea's apex. The tympanic membrane or eardrum moves in response to sound from the outer ear, which causes the fluids in the inner ear to move as well. The Organ of Corti (OC) is located in the cochlea and is made up of one row of inner hair cells (IHC) and three rows of outer hair cells (OHC) arranged along a basilar membrane. The IHCs activate auditory nerve fibers by releasing neurotransmitters in response to the waveform of a sound stimulus. Hearing loss is caused by the loss of function of the hair cells and auditory neurons. One of the main objectives of intracochlear medication delivery systems is to administer therapeutic medicines directly to the cochlea in order to induce the regeneration of these sensorineural cells.[23]

Perilymph and endolymph are the two main fluids found in the cochlea. Perilymph is somewhat comparable to cerebrospinal fluid (CSF), but it has a slightly different composition and a protein concentration that is about an order of magnitude greater.[24,25] Perilymph's composition is crucial to comprehending the kinetics of drug delivery in the cochlea since it comes into close contact with the basolateral surface of hair cells and auditory neurons.[26] The fluid called endolymph, which is found in the scala media, has an ionic composition that is comparable to that of the intracellular fluid environment and surrounds the apical surface of hair cells. The striavascularis, a highly vascularized area of the cochlea, sustains a special electrochemical environment that facilitates sound transduction by the IHC.

Perhaps the most important factor in direct intracochlear drug delivery is surgical access to the inner ear. As was previously indicated, one possible administration route is straight through the RWM, which would remove the problem of compound diffusion across the membrane that intratympanic delivery approaches face.[27] A cochleostomy, which is a surgically created hole in the cochlear bone, is another possible access route for intracochlear drug delivery.[28] The recommended entrance method for inserting multielectrode cochlear implants is a cochleostomy into the ST. Retaining residual hearing structures in receivers of cochlear implants requires minimizing the surgical trauma associated with this method. Preserving hearing structures and minimizing surgical stress are critical for medication delivery applications. Establishing a strong, leak-proof seal at the delivery system's insertion site and preventing foreign body rejection, inflammatory reactions, and biofouling of the device by the patient's immune system are additional crucial aspects of the surgical process and placement of drug delivery devices that are outside the purview of this review.

A well-established collection of electrophysiological parameters with known effects on particular hearing structures are used in functional assessment of hearing. These include the Auditory Brainstem Response (ABR) and Distortion Product OtoAcoustic Emissions (DPOAE)[29], both of which have therapeutic applications but will be covered in this article in relation to intracochlear drug delivery trials. Furthermore, drug delivery experiments frequently employ Compound Action Potential (CAP) measurements to assess delivery kinetics. Each of them can be evaluated at different frequencies; the correlation between a given frequency response and location along the cochlea's length allows the tonotopic arrangement of the cochlea to offer a spatial map of hair cell function. Two tone pips with preset sound levels and frequencies are inserted into the ear canal to measure DPOAE; the inner ear produces acoustic emissions due to the mechanical motion of the basilar membrane, which directly evaluates the OHC's function. DPOAE measurements are very helpful when used as a baseline to evaluate trauma caused by surgery in medication delivery trials.[30,31] A ball electrode placed close to the RWM is frequently used in the far-field electrocochleographic technique known as the CAP measurement, which tracks the nerve fiber response to tone pips.[32] During drug delivery investigations, this method can be utilized to map the function of hair cells via the cochlea and quantify cochlear function at particular frequencies.

An essential part of creating drug delivery systems is evaluating pharmacokinetics and pharmacodynamics.[33] Due to the small size and remote location of hearing structures, as well as the limitations associated with imaging drug transit, they provide unique hurdles for intracochlear delivery. In the end, functional evaluation of the mechanism and disease the medication-device combination is targeting will be necessary for the development of drug delivery systems for particular clinical applications. However, the introduction of surrogate molecules with established, predictable, and reversible effects on hearing can greatly aid in the development of early-stage drug delivery technologies.[34] Kinetic models that describe drug distribution as a function of delivery parameters and the anatomical and metabolic environment of the cochlea have been developed using these surrogates.[15]

b. Vestibular Diseases

The first local drug delivery application in the inner ear was transtympanic injections of gentamicin, which was used to treat Meniere's disease, a debilitating condition that involves sudden, severe attacks of vertigo that are often accompanied by hearing loss and other symptoms. The development of microcatheters, microwicks, and hydrogels for RWM application was aimed at treating Meniere's disease by providing a more uniform and well-controlled rate of delivery. Because of the hearing loss that frequently occurs during transtympanic administration of gentamicin, safety

concerns led to a dosage reduction that has improved safety while maintaining efficacy.[50,51] Bypassing possible obstacles to drug transport like the middle ear and the RWM, intrabyrinthine delivery offers the chance to administer the medication straight to the location of illness. Furthermore, patients would benefit further from the ability to enable burst administration in response to an imminent vertigo attack, maybe via an implanted intracochlear delivery device.

c. Disorders of Auditory Systems

Sensorineural Hearing Loss (SNHL), which affects over 28 million people in the US and hundreds of millions more globally, is the most common auditory disorder.[1] These figures are predicted to double over the next 20 years due to population aging. The main causes of SNHL include aging, pharmacological ototoxicity, and noise-induced damage or death of hair cells, which leads to social disengagement, communication problems, and eventually profound deafness. Current therapies rely on cochlear implants and hearing aids, which neither stop the progression of hearing loss nor restore the function of hair cells.

Intracochlear medication delivery is being explored for a number of more urgent auditory applications, many of which have sizable patient populations and all of which require substantial advancements to achieve better results. The most common of these is Noise-Induced Hearing Loss (NIHL), which can result from either prolonged or acute exposure to noise.[35] Although steroids, growth hormones, and antioxidants are being investigated, they do not yet have a direct intracochlear delivery mechanism, which limits their usefulness and occasionally results in serious side effects.[36] The prevalence of NIHL in military personnel exposed to engine noise on a regular basis or in combat situations is especially concerning. Because of their exposure to personal music players, younger patients have also been at risk for developing NIHL.

Chemotherapy and radiation therapy-induced ototoxicity[37] in cancer patients is a serious illness that calls for advancements in drug delivery technology.[38] It is well known that a sizable percentage of patients who get the widely used chemotherapy drug cisplatin may develop severe and irreversible hearing loss.[39] Current systemic strategies that include antioxidants and platinum binders seem to lessen ototoxicity, but they may also lessen the potency of cisplatin's anti-cancer effects.[40] Thus, it would be ideal to have a local delivery method that preserves the cochlea without compromising the therapeutic impact. Radiation therapy for head and neck cancers has comparable side effects, with about one-third of patients experiencing profound and permanent hearing loss.[41,42] Since high frequency hearing loss is commonly observed due to antibiotic-associated ototoxicity caused by aminoglycoside chemicals, there is a relevant opportunity.[43]

Autoimmune inner ear disease (AIED)[44,45,46] and sudden sensorineural hearing loss (SSNHL)[47] are two less common but extremely severe forms of hearing loss that may be treated by intracochlear medication delivery. High-dose systemic steroids are typically used to treat AIED, but because of the severe side effects, many patients stop their treatment and switch to cochlear implants. AIED is a possible early route to the clinic for intracochlear delivery systems in situations when there are no alternatives that protect hearing structures and safety can be evaluated with recognized, licensed drugs, even though the effectiveness of locally administered steroids is uncertain. Since substantial doses of systemic steroids with potentially harmful side effects are used in current clinical practice, SSNHL is another extremely promising option for intracochlear administration, much like AIED. using some degree of success, this condition has been treated using intratympanic administration and a catether-based strategy.[48,49]

d. Tinnitus

Pharmacologic methods, usually through transtympanic injections, have been used for more than 40 years, whereas retraining, biofeedback, and masking have had little success. It has also been shown that dexamethasone and steroid administration can moderately reduce tinnitus while maintaining hearing.[52] Nevertheless, every method has the potential to have problems when evaluating safety and effectiveness in relation to dosage and treatment length. Some of these issues may be resolved by a direct intracochlear approach, which could lead to a safer and more effective therapeutic avenue, especially when combined with programmed and changeable rates of delivery.

Mechanisms of drug delivery to the cochlea

Modalities for intracochlear drug dissolution are incompletely invasive or non-invasive. Depending on the drug and type of disease, one or the other of these approaches has advantages and disadvantages.

Methods of administration of drugs intrusively

The invasive methods are the direct and surgical ways of drug delivery driving the drugs in cochlea; it assures high local concentration at the site of action.

Cochlear targeting

Drugs can be injected via the round window membrane or cochleostomy for direct access to the cochlear fluid space. This method is widely used in preclinical research and certain clinical therapies. Conversely, high doses may lead to permanent damage to the cochlea, and the effect of drug administration is temporary.

Implantable Pumps and Reservoirs

Constant, regulated doses of drugs can be delivered continuously over extended periods of time through small pumps, such as osmotic pumps. The devices contain drugs for a long-term release given through few injections and must be surgically placed into the skull or the middle ear. Yet immune responses or device malfunction render long-term implantation seems challenging.

Drug-Eluting Implants

These types of implants include a therapeutic drug and they elute over time and often been made out of biodegradables or biocompatible. Insert them into surrounding tissues, or into the cochlea itself, while the minimal need for intervention is clearly an asset, the implant material and drug release profiles may limit their utility.

Minimally-Invasive Drug Delivery Methods

These are designed to minimize surgical access and provide a more accessible route of delivery to cochlear tissue.

Nanoparticle Carrier Drug Delivery

Drugs can be encapsulated in Nano carriers such as liposomes, polymeric nanoparticles, and micelles to cross biological barriers, such as through the round window membrane. Nanoparticles can be administered via middle ear, nasal or systemic routes depending on formulation. It offers constant decomposition, selective targeting and excellent medication stability. However, ensuring that nanoparticles adequately translate to the cochlea remains challenging.

Aerosol and Inhalation Delivery: There is also the potential for aerosol/inhalation delivery of medication through the respiratory tract to the middle ear where it can potentially access the cochlea via the Eustachian tube using nebulizers or inhalant devices.

Active Intracochlear Delivery Systems

The development of smaller pumping systems based on microfluidics technology and surgical access to the inner ear have driven advancements in the creation of active intracochlear medication delivery systems. Intracochlear delivery is often accomplished surgically through the RWM or through a cochleostomy (usually to the scala tympani, though the scala media and scala vestibuli have also been investigated potential delivery routes). The establishment of a strong fluid connection to the cochlea is one of the main challenges in intracochlear delivery; challenges have included rejection of the cannula due to a foreign body response and achieving an initial seal that does not leak at the cochleostomy site.

a. Constant Infusion Systems

Direct injections and syringe pump administration are examples of constant infusion techniques utilized for direct intracochlear delivery of drugs.[67,68,69] Gene transfer, liposomal delivery, and substances that might lessen harm related to the implantation of cochlear implants have all been employed in the former method.

According to Borkholder et al.[14], an intriguing intracochlear delivery device that uses a continual infusion pump has existed. With a continuous infusion pump and a canalostomy in the posterior semicircular canal, this technique uses a cochleostomy as a medication delivery port to improve apical delivery and decrease concentration gradients. A computational method created by Salt et al. was used to simulate and track salicylate administration from a syringe pump using DPOAE.[70] Figure 2 shows the concentration gradients produced by continuous infusion both with and without the posterior canalostomy. These findings unequivocally showed that, through a variety of processes, including likely adjusting fluidic resistance along the delivery path in relation to clearance, the canalostomy decreased the gradient of concentration from the basal to the Apical.



A diagram of a drug delivery method that involves injecting the medication into the scala tympani close to the base and opening a posterior canalostomy to lower concentration gradients by adjusting the resistance along the delivery channel. Source: Hearing Research, Vol. 268, D.A., Ref.[14]

b. Reciprocating Microfluidic Devices

For drugs delivery systems that need to mix and distribute drugs to areas far from the initial delivery site, the cochlea's tiny size and fluid volume pose a unique difficulty. The low rate of cochlear fluid clearance and, thus, the restricted amount of medication that can be injected into the cochlea in a given time frame provide problems for constant infusion

techniques, as outlined in the preceding section. The relatively lengthy and narrow pathways in the cochlear tubes and the growing difficulty of surgically accessing more apical portions of the more distant and shrinking areas that make up the lower frequency hearing response aggravate these challenges. This difficulty in transporting a medication apically via a long, narrow passage with a severely limited maximum sustained flow rate is highlighted by the previously stated work of the Borkholder group, which involved creating a canalostomy in the posterior semicircular canal to lessen concentration gradients. In order to get around this restriction, a reciprocating drug delivery system has been created that delivers zero net volume by cyclically injecting and withdrawing a fixed volume of medication.[15,16,17,18,71] By restricting the maximal flow rate and preserving the overall amount of cochlear fluid, this method aims to improve medication mixing and apical transfer. The cycle typically lasts several minutes as a combination of medication and endogenous perilymph is pulled back into the device, while the infusion phase lasts a few seconds utilizing a total drug volume of around 1 microliter. A programmed pump is used to perform this procedure cyclically. The integration of delivery components in a microfluidic chip that is implantation-sized is the subject of current research efforts.[72]



This image shows the dimensions of a microfluidic intracochlear drug delivery chip that was created by the Massachusetts Eye and Ear Infirmary and Draper Laboratory. It has a displacement chamber, valves, and fluidic vias that allow compounds to be delivered into the cochlea through a single cannula using a reciprocating delivery profile.

Cochlear Prosthesis-Mediated Delivery

For intracochlear drug administration, one of the most logical solutions is to integrate a cochlear prosthesis with the delivery system.[19,20,21,73,74] By directly stimulating the auditory nerve, a cochlear prosthesis allows people with profound or severe hearing loss to experience sound. These devices, which consist of an electrode array, speech processor, microphone, and transmitter, are implanted directly into the inner ear either via cochleostomy or the RWM.[75] Directly implanted into the cochlea, the device provides a useful method of delivering drugs to patients' inner ears for a variety of potential applications. Using drug-eluting polymers coated on the implant device and integrating active infusion pumps with the device are two delivery methods.

The use of neurotrophic agents that can preserve spiral ganglion (SG) cells and improve hearing in implanted individuals is one of the most straightforward uses of intracochlear administration with a cochlear implant.[76] In order to preserve SG cells, neurotrophic factors like fibroblast growth factor-1 and BDNF have been studied; in the former

case, SG cell survival and neurite outgrowth have been observed in culture[77], while in a guinea pig model, a combination of the two factors has been investigated as a way to preserve SG cells.[78] Furthermore, in a guinea pig model, Neurotrophin-3 has been integrated into an electrically conductive polymer coating on cochlear implant electrodes.[73]

The use of catheters and infusion pumps integrated with the implant device is being investigated for active medication delivery in the setting of a cochlear implant. This strategy is motivated in part by the goal of minimizing the structural harm that the cochlear implant causes, which would allow the device to be utilized by patients who have less severe hearing loss than those who would normally receive a conventional implant. By using a shorter electrode or a partial implantation of a regular electrode, this method restricts the area of hearing structure damage to the highest frequencies.



Two approaches of medicine distribution from a cochlear implant device are illustrated. (a) A catheter prototype intended for atraumatic cochlear insertion is seen connected to a syringe and placed within a cochlear model. The catheter's architecture is extremely flexible because to its thin walls and tiny wall diameter, which allow it to reach a maximum length of 20 mm. (b) A catheter-infused green dye is used to illuminate the electrode array as it is inserted. (c) Improved medication distribution in the cochlea is made possible by laser-drilled holes with a diameter of 50 microns. (d) Elution of medical-grade silicone elastomer with pharmaceutical-grade dexamethasone; the medication is in the bottom (opaque) portion.

Passive Intracochlear Delivery Systems

Depending on whether power and electrical controls must be included into the device, intracochlear delivery methods can be generally categorized as either passive or active. Many of the intracochlear administration techniques that have been investigated—mostly in animal models in research labs, but some that have undergone clinical testing—are summed up in the discussion that follows.

Transtympanic Pathways

This study focuses on direct intracochlear delivery, which involves surgically positioning a delivery device in close proximity to cochlear fluid and structures. A brief discussion of previous intratympanic delivery methods will be given in order to set the scene for the development of direct intracochlear devices. The traditional indirect method of cochlear medication administration involves introducing substances into the middle ear and then allowing them to be absorbed into the inner ear. The simplest method involves injecting a needle into the middle ear; a more complex process

involves introducing the medication through a myringotomy, occasionally through a tympanostomy tube.[53] Meniere's illness and SSNHL have both been treated with a myringotomy, which involves delivering medications straight to the round window membrane via a Silverstein MicroWick®.[11] The use of an implanted microcatheter positioned in the round window niche has been documented by Plontke[54]; 25 patients have undergone testing of this technique for the treatment of SSNHL. IT injections of OTO-104, a steroid that has been demonstrated in a Phase 1b study to lessen symptom intensity without side effects, have been used to treat Meniere's illness in recent years.[55]

Several organizations have investigated the use of hydrogels and nanoparticles as delivery vehicles to enhance dose control during intratympanic administration. These systems have a significant benefit over previous liquid delivery sources in that they may use controlled release matrices to give continuous supply for extended periods of time, significantly extending the length of performance. For intracochlear treatment, several compositions of nanoparticles, including biodegradable and non-biodegradable nanoparticle delivery systems, have been investigated. Nanoparticles provide the promise for more prolonged and well-controlled administration. Tamura et al. have published a composition of bioresorbable nanoparticles based on poly(lactic co-glycolic) acid (PLGA).[56] This study demonstrated that the concentration of a fluorescent label attached to the nanoparticles in the cochlea significantly increased in comparison to levels observed when the fluorescent label was introduced either systemically or by application as a free molecule to the RWM, confirming the positive effects of nanoparticles on pharmacokinetics. In order to improve apical delivery, magnetic fields have been employed to direct superparamagnetic nanoparticles down the chinchilla cochlea[57], albeit there is conflicting information about deeper penetration. Gene therapy has made use of liposomal delivery[58]; the liposomes can be administered using osmotic pump or by injection.

For a variety of therapeutic uses, hydrogels show remarkable adaptability as drug delivery systems.[59] Chemical methods, electrical stimulation, temperature, pH, and pressure are some of the triggers that cause the hydrogel's medicinal payload to be released. A hydrogel matrix applied to the RWM has been used to distribute brain-derived growth factor (BDNF)[60], with SGN cells exhibiting protective benefits. There have been reports of siloxane-based hydrogel systems[61], but biodegradable hydrogels, such as PLGA[62], have received a lot of attention. Topical administration of insulin-like growth factor (IGF-1) has been demonstrated in recent clinical trials to enhance hearing in around half of patients with no side effects.[63]

Osmotic Pumps

Drugs can be delivered directly to tissues using osmotic pumps, eliminating the need for power sources or external connections. They work by creating an osmotic gradient that pushes medication out of a canister and, in the case of intracochlear delivery in the inner ear via a cannula, at a pace dictated by the device's design. Osmotic pumps can transport large molecules, proteins, and peptides, which is why they have been employed in many intracochlear applications. In a pioneering example of intracochlear medication administration, Kingma et al.[64] surgically implanted a micro-injector close to the scala tympani's basal turn in guinea pigs. For as long as two weeks, the animals' auditory brainstem response was observed after they were injected with either tetrodotoxin or saline solution as a control. Prieskorn and Miller[10] described the use of osmotic pumps (Alza Corp.) for chronic intracochlear administration and cannulae that are inserted for repeated medication infusions. According to Lalwani, lentiviral vectors can be used to transfer genes.[65] Osmotic pumps are also being studied for their ability to protect against ototoxicity during cisplatin-

based chemotherapy; it has been demonstrated that sodium thiosulfate injected through a glass cannula from an osmotic pump shields hair cells from the harmful effects of cisplatin.[66]

Medical Uses

Intracochlear drug delivery aims to treat hearing loss and other cochlear disorders. Multiple treatment modalities are being explored:

Protection from Ototoxicity

Ototoxicity causes permanent hearing loss by ototoxic medications, which include many aminoglycoside antibiotics and some platinum-based chemotherapy. Intracochlear drug delivery methods are being investigated for targeted cochlear delivery of protective agents such as antioxidants, free radical scavengers, or otoprotective drugs (e.g., N-acetyl cysteine). This may help preserve hearing by preventing ototoxicity-induced cochlear damage.

Gene therapy

Gene therapy has the potential to treat the underlying genetic causes of hearing loss by delivering therapeutic genes into cochlear cells. Adeno-associated viral (AAV) vectors and CRISPR-Cas9 technologies have been attempted to be introduced into the cochlea.

Cochlear Regeneration

Targeting cochlear regeneration, particularly the regeneration of lost hair cells, is one of the most popular topics in cochlear drug delivery. Researchers are investigating shortcuts using stem cell-based treatments and growth factors including brain-derived neurotropic factor (BDNF) and glial cell line-derived neurotropic factor (GDNF) to promote hair cell regeneration. Intracochlear medication delivery systems can directly target these traits to the cochlea.

Fibro proliferative disease treatments

Cochlear inflammation and fibrosis can cause progressive hearing loss. Intracochlear drug delivery systems have therefore been explored for the localized delivery of anti-inflammatory (e.g., corticosteroid] or anti-fibrotic drugs to reduce cochlear inflammation and fibrosis following trauma or infection.

Challenges in the Delivery of Otologic Therapeutics to the Inner Ear

Though some strides have been made, intracochlear medication delivery remains a challenge. There are, however, substantial hurdles that must be addressed to make these treatments beneficial:

Anatomical Barriers

The blood-labyrinth barrier, the circular window membrane, the bone wall, and the tight bonds between cochlear cells enclose the cochlea. The effectiveness of medicine delivery is restricted by these obstacles. Developing solutions to improve the importation of drugs requires an understanding of how porous these barriers are.

Drug stability and release control

A Long-term controlled release of drugs long might not be easy to maintain Fast removal or degradation of the drug from the cochlea may limit the clinical usefulness of drugs given by an intracochlear route of administration. Advanced drug-eluting implants or nanoparticles with ideal release properties are needed for long-term effectiveness.

Toxicity and Biocompatibility

High local medication concentrations, particularly those of neurotoxic drugs, provide a significant risk of local toxicity. Therefore, for medication carriers to be successful, they must be biocompatible, meaning they won't harm cochlear structures or trigger a local inflammatory response. Immune Responses: Immune system reactions to implanted devices or nanoparticles may cause inflammation or the rejection of the drug delivery system. Biodegradable and non-immunogenic materials are being researched to reduce these effects.

Regulatory and Therapeutic Translation

Transitioning from animal research to human clinical trials is still not always feasible. Regulatory approval may need extensive safety and efficacy testing, particularly for gene treatments and Nano medicines. Clinical validation of innovative medication delivery systems beyond laboratory testing and pilot investigations is necessary to determine the long-term benefits and risks of treating the cochlea.

Prospects for the Future

Novel Nanomaterial's: Nano carriers, such as lipid-based nanoparticles, biodegradable polymers, and hybrid nanoparticles, have the potential to enhance the precision and efficacy of drug delivery to the cochlea. They can be engineered to have low toxicity, controlled release and targeting. Gene and Cell-Based Treatments: As stem cell and gene therapies advance, intracochlear medication delivery techniques may be crucial for delivering growth factors or therapeutic genes to promote cochlear healing and restore hearing.

Combination Therapies

The synergistic benefits of employing cochlear implants or hearing aids in conjunction with medication delivery systems may enhance the mechanical and biological components of hearing restoration.4. Personalized Medicine: to achieve customised Drug Delivery methods we have to develop pharmacogenomics and biomarker identification. By considering patients specific profile cochlear treatment can be made effective and safe by modifying drug formulation.

CONCLUSION

Intracochlear drug injection is a promising treatment option for cochlear issues, including hearing loss. Despite significant progress, challenges remain in overcoming anatomical barriers, controlling drug release, ensuring biocompatibility, and generating long-lasting therapeutic advantages. Thanks to advancements in targeted drug delivery methods, gene therapy, and nanotechnology, intracochlear medication administration has the potential to revolutionize the management of hearing loss and pave the way for more effective, minimally invasive therapies. Future research, especially clinical trials, will be crucial to incorporating these developments into clinical practice.

REFERENCES

1. Holley MC. Keynote review: The auditory system, hearing loss and potential targets for drug development. Drug Discov Today, 2005; 10(19): 1269–82. This paper is of considerable interest as it covers a broad spectrum of therapeutic opportunities for drug delivery systems to the inner ear. [PubMed: 16214671]
2. http: //www.vba.va.gov/REPORTS/abr/index.asp
3. DePalma RG, Burris DG, Champion HR, et al. Blast injuries. N Engl J Med, 2005; 352(13): 1335– 42. [PubMed: 15800229]

4. Swan EE, Mescher MJ, Sewell WF, et al. Inner ear drug delivery for auditory applications. Adv Drug Deliv Rev., 2008; 60(15): 1583–99. [PubMed: 18848590]
5. McCall AA, Swan EE, Borenstein JT, et al. Drug delivery for treatment of inner ear disease: current state of knowledge. Ear Hear, 31(2): 156–65. [PubMed: 19952751]
6. Borkholder DA. State-of-the-art mechanisms of intracochlear drug delivery. Curr Opin Otolaryngol Head Neck Surg, 2008; 16(5): 472–7. [PubMed: 18797291]
7. Theeuwes F, Yum SI. Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations. Ann Biomed Eng., 1976; 4(4): 343–53. [PubMed: 1020825]
8. Theeuwes F, Yum SI, Haak R, et al. Systems for triggered, pulsed, and programmed drug delivery. Ann N Y Acad Sci., 1991; 618: 428–40. [PubMed: 2006800]
9. Brown JN, Miller JM, Altschuler RA, et al. Osmotic pump implant for chronic infusion of drugs into the inner ear. Hear Res. 1993; 70(2): 167–72. [PubMed: 8294261]
10. Prieskorn DM, Miller JM. Technical report: chronic and acute intracochlear infusion in rodents. Hear Res., 2000; 140(1–2): 212–5. [PubMed: 10675648]
11. Silverstein H. Use of a new device, the MicroWick, to deliver medication to the inner ear. Ear Nose Throat J., 1999; 78(8): 595–8. 600. [PubMed: 10485154]
12. Silverstein H, Thompson J, Rosenberg SI, et al. Silverstein MicroWick. Otolaryngol Clin North Am., 2004; 37(5): 1019–34. [PubMed: 15474108]
13. Hill SL 3rd, Digges EN, Silverstein H, et al. Long-term follow-up after gentamicin application via the Silverstein MicroWick in the treatment of Meniere's disease. Ear Nose Throat J., 2006; 85(8): 494, 496, 498. [PubMed: 16999055]
14. Borkholder DA, Zhu X, Hyatt BT, et al. Murine intracochlear drug delivery: reducing concentration gradients within the cochlea. Hear Res., 268: 1–2. 2–11. This paper is of interest regarding the use of fluid mechanical approaches and simulations to control and optimize drug transport in the cochlea.
15. Chen Z, Kujawa SG, McKenna MJ, et al. Inner ear drug delivery via a reciprocating perfusion system in the guinea pig. J Control Release, 2005; 110(1): 1–19. [PubMed: 16274830]
16. Fiering J, Mescher MJ, Swan EEL, et al. Local drug delivery with a self-contained, programmable, microfluidic system. Biomed Microdevices. 2009; 11(3): 571–8. [PubMed: 19089621]
17. Sewell, WF.; Borenstein, JT.; Chen, Z., et al. Audiol Neurootol. Vol. 14. 2009. Development of a microfluidics-based intracochlear drug delivery device; p. 411-22. This paper is of interest based on the investigation of the parameter space for delivery to understand and optimize the safety and efficacy of future therapeutic applications.
18. Pararas EEL, Chen Z, Fiering J, et al. Kinetics of reciprocating drug delivery to the inner ear. J Controlled Release. 10.1016/j.jconrel.2011.02.021
19. Garnham C, Reetz G, Jolly C, et al. Drug delivery to the cochlea after implantation: consideration of the risk factors. Cochlear Implants Int., 2005; 6(Suppl 1): 12–4. [PubMed: 18792345]
20. Hochmair I, Nopp P, Jolly C, et al. MED-EL Cochlear implants: state of the art and a glimpse into the future. Trends Amplif., 2006; 10(4): 201–19. [PubMed: 17172548]
21. Shepherd RK, Xu J. A multichannel scala tympani electrode array incorporating a drug delivery system for chronic intracochlear infusion. Hear Res., 2002; 172(1–2): 92–8. This paper is of considerable interest because it offers a

potentially near-term avenue for clinical application of intracochlear drug delivery systems in combination with a clinically approved device. [PubMed: 12361871]

22. Schuknecht, H. Pathology of the ear. Lea and Febiger; Malvern, PA: 1993.
23. Staecker H. Broadening the spectrum of treatment options for SNHL. Arch Otolaryngol Head Neck Surg, 2005; 131(8): 734. [PubMed: 16103310]
24. Medina JE, Drescher DG. The amino-acid content of perilymph and cerebrospinal fluid from guinea-pigs and the effect of noise on the amino-acid composition of perilymph. Neuroscience, 1981; 6(3): 505–9. [PubMed: 7219728]
25. Scheibe F, Haupt H. Biochemical differences between perilymph, cerebrospinal fluid and blood plasma in the guinea pig. Hear Res., 1985; 17(1): 61–6. [PubMed: 3997682]
26. Swan EE, Peppi M, Chen Z, et al. Proteomics analysis of perilymph and cerebrospinal fluid in mouse. Laryngoscope, 2009; 119(5): 953–8. [PubMed: 19358201]
27. Banfai P, Hortmann G, Kubik S, et al. Projection of the spiral cochlear canal on the medial wall of the tympanic cavity with regard to the cochlear implant. Scand Audiol Suppl., 1979; 11: 157–70. [PubMed: 299183]
28. Adunka OF, Radeloff A, Gstoettner WK, et al. Scala tympani cochleostomy II: topography and histology. Laryngoscope, 2007; 117(12): 2195–200. [PubMed: 17909447]
29. Conn, MP. Sourcebook of Models for Biomedical Research. Vol. Chapter 32. Springer; New York: 2007.
30. Telischi FF, Widick MP, Lonsbury-Martin BL, et al. Monitoring cochlear function intraoperatively using distortion product otoacoustic emissions. Am J Otol. 1995; 16(5): 597–608. [PubMed: 8588664]
31. Telischi FF, Stagner B, Widick MP, et al. Distortion-product otoacoustic emission monitoring of cochlear blood flow. Laryngoscope. 1998; 108(6): 837–42. [PubMed: 9628498]
32. Gouveris H, Mann W. Association between surgical steps and intraoperative auditory brainstem response and electrocochleography waveforms during hearing preservation vestibular schwannoma surgery. Eur Arch Otorhinolaryngol. 2009; 266(2): 225–9. [PubMed: 18553092]
33. Salt AN, Plontke SK. Principles of local drug delivery to the inner ear. Audiol Neurootol. 2009; 14(6): 350–60. This paper is of considerable interest because it covers a wide range of concepts and challenges associated with drug delivery to the inner ear, including pharmacokinetic principles and computational approaches. [PubMed: 19923805]
34. Littman T, Bobbin RP, Fallon M, et al. The quinoxalinediones DNOX, CNOX and two related congeners suppress hair cell-to-auditory nerve transmission. Hear Res. 1989; 40(1–2): 45–53. [PubMed: 2570055]
35. Sendowski I, Abaamrane L, Raffin F, et al. Therapeutic efficacy of intra-cochlear administration of methylprednisolone after acoustic trauma caused by gunshot noise in guinea pigs. Hear Res. 2006; 221(1–2): 119–27. [PubMed: 17008037]
36. Lynch ED, Kil J. Compounds for the prevention and treatment of noise-induced hearing loss. Drug Discov Today. 2005; 10(19): 1291–8. [PubMed: 16214673]
37. Chiu LL, Cunningham LL, Raible DW, et al. Using the zebrafish lateral line to screen for ototoxicity. J Assoc Res Otolaryngol. 2008; 9(2): 178–90. [PubMed: 18408970]
38. Rybak LP, Kelly T. Ototoxicity: bioprotective mechanisms. Curr Opin Otolaryngol Head Neck Surg. 2003; 11(5): 328–33. [PubMed: 14502062]
39. Rybak LP. Cis-platinum associated hearing loss. J Laryngol Otol. 1981; 95(7): 745–7. [PubMed: 7195923]

40. Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discov Today. 2005; 10(19): 1313–21. [PubMed: 16214676]
41. Bhandare N, Antonelli PJ, Morris CG, et al. Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys. 2007; 67(2): 469–79. [PubMed: 17236969]
42. Jereczek-Fossa BA, Zarowski A, Milani F, et al. Radiotherapy-induced ear toxicity. Cancer Treat Rev. 2003; 29(5): 417–30. [PubMed: 12972360]
43. Himeno C, Komeda M, Izumikawa M, et al. Intra-cochlear administration of dexamethasone attenuates aminoglycoside ototoxicity in the guinea pig. Hear Res. 2002; 167(1–2): 61–70. [PubMed: 12117531]
44. Ryan AF, Harris JP, Keithley EM, et al. Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol Suppl. 2002; (548): 38–43. [PubMed: 12211356]
45. Yang GS, Song HT, Keithley EM, et al. Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss. Am J Otol. 2000; 21(4): 499–504. [PubMed: 10912694]
46. Matteson EL, Fabry DA, Strome SE, et al. Autoimmune inner ear disease: diagnostic and therapeutic approaches in a multidisciplinary setting. J Am Acad Audiol. 2003; 14(4): 225–30. [PubMed: 12940706]
47. Mushier I, Bouccara D, Atassi-Dumont M, et al. Treatments of idiopathic sudden sensorineural hearing loss: retrospective study of 144 cases]. Rev Laryngol Otol Rhinol (Bord). 1998; 119(2): 119–28. [PubMed: 9770055]
48. Kopke RD, Hoffer ME, Wester D, et al. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol. 2001; 22(4): 475–9. [PubMed: 11449103]
49. Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol. 2001; 22(1): 18–23. [PubMed: 11314710]
50. Harner SG, Driscoll CL, Facer GW, et al. Long-term follow-up of transtympanic gentamicin for Meniere's syndrome. Otol Neurotol. 2001; 22(2): 210–4. [PubMed: 11300271]
51. Chia SH, Gamst AC, Anderson JP, et al. Intratympanic gentamicin therapy for Meniere's disease: a meta-analysis. Otol Neurotol. 2004; 25(4): 544–52. [PubMed: 15241234]
52. Hoffer ME, Wester D, Kopke RD, et al. Transtympanic management of tinnitus. Otolaryngol Clin North Am. 2003; 36(2): 353–8. [PubMed: 12856303]
53. Licameli G, Johnston P, Luz J, et al. Phosphorylcholine-coated antibiotic tympanostomy tubes: are post-tube placement complications reduced? Int J Pediatr Otorhinolaryngol. 2008; 72(9): 1323–8. [PubMed: 18635268]
54. Plontke S, Lowenheim H, Preyer S, et al. Outcomes research analysis of continuous intratympanic glucocorticoid delivery in patients with acute severe to profound hearing loss: basis for planning randomized controlled trials. Acta Otolaryngol. 2005; 125(8): 830–9. [PubMed: 16158529]
55. http: //clinicaltrials.gov/ct2/show/NCT01084525
56. Tamura T, Kita T, Nakagawa T, et al. Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope. 2005; 115(11): 2000–5. [PubMed: 16319613]
57. Ge X, Jackson RL, Liu J, et al. Distribution of PLGA nanoparticles in chinchilla cochleae. Otolaryngol Head Neck Surg. 2007; 137(4): 619–23. [PubMed: 17903580]
58. Wareing M, Mhatre AN, Pettis R, et al. Cationic liposome mediated transgene expression in the guinea pig cochlea. Hear Res. 1999; 128(1–2): 61–9. [PubMed: 10082284]
59. Saltzman, WM. Engineering Principles for Drug Delivery. Oxford; New York: 2001.

60. Endo T, Nakagawa T, Kita T, et al. Novel strategy for treatment of inner ears using a biodegradable gel. Laryngoscope. 2005; 115(11): 2016–20. [PubMed: 16319616]
61. Arnold W, Senn P, Hennig M, et al. Novel slow-and fast-type drug release round-window microimplants for local drug application to the cochlea: an experimental study in guinea pigs. Audiol Neurootol. 2005; 10(1): 53–63. [PubMed: 15591792]
62. Ito J, Endo T, Nakagawa T, et al. A new method for drug application to the inner ear. ORL J Otorhinolaryngol Relat Spec. 2005; 67(5): 272–5. [PubMed: 16374059]
63. Nakagawa T, Sakamoto T, Hiraumi H, et al. Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial. BMC Med. 2010; 8: 76. [PubMed: 21108784]
64. Kingma GG, Miller JM, Myers MW, et al. Chronic drug infusion into the scala tympani of the guinea pig cochlea. J Neurosci Methods. 1992; 45(1–2): 127–34. [PubMed: 1491594]
65. Carvalho GJ, Lalwani AK. The effect of cochleostomy and intracochlear infusion on auditory brain stem response threshold in the guinea pig. Am J Otol. 1999; 20(1): 87–90. [PubMed: 9918180]
66. Wang J, Lloyd Faulconbridge RV, Fetoni A, et al. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology. 2003; 45(3): 380–93. [PubMed: 12871655]
67. Praetorius M, Baker K, Brough DE, et al. Pharmacodynamics of adenovector distribution within the inner ear tissues of the mouse. Hear Res. 2007; 227(1–2): 53–8. [PubMed: 17081711]
68. Oestreicher E, Arnold W, Ehrenberger K, et al. New approaches for inner ear therapy with glutamate antagonists. Acta Otolaryngol. 1999; 119(2): 174–8. [PubMed: 10320071]
69. Stover T, Yagi M, Raphael Y, et al. Cochlear gene transfer: round window versus cochleostomy inoculation. Hear Res. 1999; 136(1–2): 124–30. [PubMed: 10511631]
70. Plontke SK, Siedow N, Wegener R, et al. Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model. Audiol Neurootol. 2007; 12(1): 37–48. [PubMed: 17119332]
71. Mescher MJ, Swan EE, Fiering J, et al. Fabrication Methods and Performance of LowPermeability Microfluidic Components for a Miniaturized Wearable Drug Delivery System. J Microelectromech Syst. 2009; 18(3): 501–510. [PubMed: 20852729]
72. Handzel O, Wang H, Fiering J, et al. Mastoid cavity dimensions and shape: method of measurement and virtual fitting of implantable devices. Audiol Neurootol. 2009; 14(5): 308–14. [PubMed: 19372649]
73. Richardson RT, Wise AK, Thompson BC, et al. Polypyrrole-coated electrodes for the delivery of charge and neurotrophins to cochlear neurons. Biomaterials. 2009; 30(13): 2614–24. [PubMed: 19178943].
74. Paasche G, Gibson P, Averbeck T, et al. Technical report: modification of a cochlear implant electrode for drug delivery to the inner ear. Otol Neurotol. 2003; 24(2): 222–7. [PubMed: 12621336]
75. Briggs RJ, Tykocinski M, Xu J, et al. Comparison of round window and cochleostomy approaches with a prototype hearing preservation electrode. Audiol Neurootol. 2006; 11(Suppl 1): 42–8. [PubMed: 17063010]
76. Incesulu A, Nadol JB Jr. Correlation of acoustic threshold measures and spiral ganglion cell survival in severe to profound sensorineural hearing loss: implications for cochlear implantation. Ann Otol Rhinol Laryngol. 1998; 107(11 Pt 1): 906–11. [PubMed: 9823838]
77. Warnecke A, Wissel K, Hoffman A, et al. The biological effects of cell-delivered brain-derived neurotrophic factor on cultured spiral ganglion cells. Neuroreport. 2007; 18(16): 1683–6. [PubMed: 17921868]

78. Miller JM, Le Prell CG, Prieskorn DM, et al. Delayed neurotrophin treatment following deafness rescues spiral ganglion cells from death and promotes regrowth of auditory nerve peripheral processes: effects of brain-derived neurotrophic factor and fibroblast growth factor. J Neurosci Res. 2007; 85(9): 1959–69. [PubMed: 17492794]
79. Pettingill LN, Richardson RT, Wise AK, et al. Neurotrophic factors and neural prostheses: potential clinical applications based upon findings in the auditory system. IEEE Trans Biomed Eng. 2007; 54(6 Pt 1): 1138–48. [PubMed: 17551571]